-
2024-516443-57-00
4
2023-10-11
Patients with Hepatocellular Carcinoma (HCC) and Child-Pugh B, ALBI gr
-
2023-510541-25-00
1
2023-10-09
Relapsed/Refractory B-cell Malignancies
-
2024-512759-19-00
4
2023-04-20
first suspected infection with Mycobacterium tuberculosis in the lungs
-
2024-511866-36-00
5
2023-03-11
patients hospitalized in ICU with ESBL-producing Enterobacteriaceae se
-
2024-514913-37-00
11
2023-01-12
Respiratory distress
-
2024-515354-24-00
9
2022-05-18
Low risk myelodysplastic syndrom without RS having failed or being ine
-
2024-512953-26-00
5
2021-07-06
intermediate-stage hepatocellular carcinoma
-
2024-513427-17-00
6
2021-05-20
Well controlled severe allergic asthma
-
2024-511868-83-00
5
2021-02-05
Antisynthetase syndrome-related interstitial lung disease
-
2024-511904-18-00
10
2020-07-08
Pancreatic adenocarcinoma (PAC)
-
2022-501254-10-00
5
2018-08-24
Advanced tumors
-
2024-516103-16-00
4
2015-12-04
Acute Lymphoblastic Leukemia (ALL) in younger adults (18-59 years)
-
2023-506027-29-00
5
2014-10-01
Children, adolescents and adults with newly diagnosed diffuse intrinsi
-
2024-516873-57-00
10
2026-01-13
Acute myeloid leukemia in adults aged 18 to 60
-
2024-518339-12-00
4
2025-07-08
Idiopathic Pulmonary Fibrosis
-
2023-505278-13-00
4
2024-10-01
-women with an inflammatory HCA proven at histology and with at least
-
2023-509190-23-00
5
2024-09-03
Atherosclerotic Cardiovascular Disease
Elevated lp(a)
-
2023-504176-25-00
9
2024-08-08
Acute Myeloid Leukemia
-
2024-513718-37-00
4
2024-08-01
IGHV unmutated patients with high-risk stage A CLL features.
-
2022-502954-15-00
4
2024-06-21
Idiopathic pulmonary fibrosis
-
2022-502099-22-01
5
2024-04-29
HIV-1 Infection
-
2023-504471-25-00
5
2024-03-01
Fibrotic Lung Disease
-
2024-511169-12-00
5
2023-03-28
Non-Small Cell Lung Cancer
-
2022-501217-31-00
10
2023-03-09
Hepatocellular carcinoma